Sign in

CIK 0001211583 · Non-accelerated filer<br>Smaller reporting company

FENNEC PHARMACEUTICALS INC.

Sign in to watch
Ticker
FENC
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
British Columbia, Canada
Entity type
operating
Phone
(919) 636-4530
Business address
PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709
Former names
ADHEREX TECHNOLOGIES INC
  1. 4 Planned sale CHIEF EXECUTIVE OFFICER sold 88,583 shares at an average $10.82 ($958,669)
  2. 4 Planned sale CHIEF EXECUTIVE OFFICER sold 40,584 shares at an average $10.78 ($437,451)
  3. 4 Open-market buy CHIEF FINANCIAL OFFICER bought 12,500 shares
  4. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 29,167 shares
  5. 4 Planned sale Director sold 2,114 shares at $10.97 ($23,191)
  6. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 13,975 shares at $10.90 ($152,346)
  7. 4 Planned sale CHIEF FINANCIAL OFFICER sold 13,975 shares at $11.00 ($153,690)
  8. 4 Planned sale CHIEF FINANCIAL OFFICER sold 30,000 shares at an average $10.53 ($315,750)
  9. 4 Open-market sale CHIEF EXECUTIVE OFFICER sold 3,656 shares at $11.55 ($42,227)
  10. 4 Planned sale Director sold 1,390 shares at $10.90 ($15,151)
  11. 4 Planned sale Director sold 269 shares at $8.25 ($2,219)
  12. 4 Option exercise Director acquired 213,825 shares (option exercise)
  13. 4 Open-market sale CHIEF EXECUTIVE OFFICER sold 25,044 shares at an average $7.76 ($194,267)
  14. 4 Option exercise CHIEF EXECUTIVE OFFICER acquired 74,793 shares (option exercise)
  15. 4 Planned sale Director sold 673 shares at $7.85 ($5,283)
  16. 4 Derivatives Options or other derivatives
  17. 4 Planned sale Director sold 6,796 shares at $8.17 ($55,523)
  18. 4 Planned sale Director sold 2,207 shares at $8.47 ($18,693)
  19. 4 Planned sale CHIEF FINANCIAL OFFICER sold 25,000 shares at an average $8.93 ($223,325)
  20. 4 Derivatives Options or other derivatives

Page 10 of 18 · 349 filings